UA52679C2 - Фармацевтична композиція, що містить велику кількість одиниць трамадолу, і спосіб її приготування - Google Patents
Фармацевтична композиція, що містить велику кількість одиниць трамадолу, і спосіб її приготування Download PDFInfo
- Publication number
- UA52679C2 UA52679C2 UA99021086A UA99021086A UA52679C2 UA 52679 C2 UA52679 C2 UA 52679C2 UA 99021086 A UA99021086 A UA 99021086A UA 99021086 A UA99021086 A UA 99021086A UA 52679 C2 UA52679 C2 UA 52679C2
- Authority
- UA
- Ukraine
- Prior art keywords
- release
- pharmaceutical composition
- composition according
- active substance
- granules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 11
- 238000009472 formulation Methods 0.000 title abstract description 6
- 238000002360 preparation method Methods 0.000 title description 4
- 239000000126 substance Substances 0.000 claims abstract description 21
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims abstract description 18
- 229960004380 tramadol Drugs 0.000 claims abstract description 18
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims abstract description 18
- 239000012528 membrane Substances 0.000 claims abstract description 15
- 230000000979 retarding effect Effects 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000013543 active substance Substances 0.000 claims description 54
- 239000008187 granular material Substances 0.000 claims description 53
- 229920001249 ethyl cellulose Polymers 0.000 claims description 25
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 25
- 239000001856 Ethyl cellulose Substances 0.000 claims description 24
- 229920001800 Shellac Polymers 0.000 claims description 20
- 235000013874 shellac Nutrition 0.000 claims description 20
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 19
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 18
- 239000004208 shellac Substances 0.000 claims description 16
- 229940113147 shellac Drugs 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 11
- 230000003111 delayed effect Effects 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 230000006203 ethylation Effects 0.000 claims description 3
- 238000006200 ethylation reaction Methods 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 3
- 239000008188 pellet Substances 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 12
- 229960003107 tramadol hydrochloride Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- -1 Aegosia 200 Chemical compound 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- MVIBAGVZHYCVLJ-UHFFFAOYSA-N azane;methyl prop-2-enoate Chemical compound N.COC(=O)C=C MVIBAGVZHYCVLJ-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glanulating (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19630035A DE19630035A1 (de) | 1996-07-25 | 1996-07-25 | Tramadol Multiple Unit Formulierungen |
| PCT/EP1997/003934 WO1998004249A2 (fr) | 1996-07-25 | 1997-07-19 | Formulations de tramadol a unites multiples |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA52679C2 true UA52679C2 (uk) | 2003-01-15 |
Family
ID=7800815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99021086A UA52679C2 (uk) | 1996-07-25 | 1997-07-19 | Фармацевтична композиція, що містить велику кількість одиниць трамадолу, і спосіб її приготування |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US5955104A (fr) |
| EP (1) | EP0917463B1 (fr) |
| JP (1) | JP3631762B2 (fr) |
| KR (1) | KR100474793B1 (fr) |
| CN (1) | CN1111402C (fr) |
| AR (1) | AR008002A1 (fr) |
| AT (1) | ATE213408T1 (fr) |
| AU (1) | AU737121B2 (fr) |
| BG (1) | BG63708B1 (fr) |
| BR (1) | BR9710761A (fr) |
| CA (1) | CA2211284C (fr) |
| CZ (1) | CZ296964B6 (fr) |
| DE (2) | DE19630035A1 (fr) |
| DK (1) | DK0917463T3 (fr) |
| EE (1) | EE03742B1 (fr) |
| ES (1) | ES2171268T3 (fr) |
| HK (1) | HK1020876A1 (fr) |
| HU (1) | HU227971B1 (fr) |
| IL (1) | IL127915A (fr) |
| NO (1) | NO324207B1 (fr) |
| NZ (1) | NZ333822A (fr) |
| PL (1) | PL188834B1 (fr) |
| PT (1) | PT917463E (fr) |
| RU (1) | RU2201223C2 (fr) |
| SK (1) | SK285300B6 (fr) |
| TW (1) | TW495363B (fr) |
| UA (1) | UA52679C2 (fr) |
| WO (1) | WO1998004249A2 (fr) |
| ZA (1) | ZA975408B (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034377B2 (en) | 2004-09-01 | 2015-05-19 | Purdue Pharma, L.P. | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| US6197347B1 (en) * | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
| US6312728B1 (en) * | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| DE19901686A1 (de) * | 1999-01-18 | 2000-07-20 | Gruenenthal Gmbh | Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung |
| DE19901687B4 (de) * | 1999-01-18 | 2006-06-01 | Grünenthal GmbH | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
| CN1202815C (zh) * | 1999-08-31 | 2005-05-25 | 格吕伦塔尔有限公司 | 含有曲马朵糖精盐的持续释放给药剂型 |
| DE19940944B4 (de) * | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retardierte, orale, pharmazeutische Darreichungsformen |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR20130010512A (ko) | 1999-10-29 | 2013-01-28 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| US6620431B1 (en) | 2000-04-17 | 2003-09-16 | Charles Signorino | Shellac film coatings providing release at selected pH and method |
| US20030157247A1 (en) * | 2000-06-14 | 2003-08-21 | Yoshiro Chikami | Method for producing coated bioactive granule |
| HUP0301416A2 (hu) * | 2000-07-06 | 2003-09-29 | Delsys Pharmaceutical Corporation | Javított tiroid hormon gyógyszerformák |
| KR100960200B1 (ko) | 2000-10-30 | 2010-05-27 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
| US20030104976A1 (en) * | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
| SI1476138T1 (sl) * | 2002-02-21 | 2012-07-31 | Valeant Internat Barbados Srl | Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola |
| US8128957B1 (en) * | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| DE60335426D1 (de) * | 2002-08-15 | 2011-01-27 | Euro Celtique Sa | Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten |
| DK1424068T3 (da) * | 2002-11-27 | 2006-11-27 | Oramon Arzneimittel Gmbh & Co | Fremgangsmåde til fremstilling af pellets indeholdende et tri- eller tetra-cyklisk antidepressivum samt farmaceutiske tilberedninger indeholdende disse pellets |
| CN100500130C (zh) | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | 缓释制剂及其制备方法 |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10341414A1 (de) * | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| WO2005034859A2 (fr) * | 2003-10-03 | 2005-04-21 | Elite Laboratories Inc. | Formulations d'opioides a liberation prolongee et methode d'utilisation des formulations |
| US8163114B2 (en) * | 2004-04-07 | 2012-04-24 | New Jersey Institute Of Technology | Netshape manufacturing processes and compositions |
| US20070224281A1 (en) * | 2004-07-22 | 2007-09-27 | Amorepacific Corporation | Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof |
| US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US11311490B2 (en) * | 2005-08-10 | 2022-04-26 | Add Advanced Drug Delivery Technologies Ltd. | Oral preparation with controlled release |
| WO2007132293A2 (fr) * | 2005-11-10 | 2007-11-22 | Circ Pharma Research And Development Limited | Administration à prise unique quotidienne de médicaments agissant sur le système nerveux central |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| US20070264335A1 (en) * | 2006-05-09 | 2007-11-15 | Sherman Bernard C | Modified release tablets comprising tramadol |
| WO2008094877A2 (fr) * | 2007-01-30 | 2008-08-07 | Drugtech Corporation | Compositions pour l'administration orale de produits pharmaceutiques |
| US10888521B2 (en) * | 2007-03-02 | 2021-01-12 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| CN101095666B (zh) * | 2007-08-14 | 2010-10-06 | 石药集团欧意药业有限公司 | 一种盐酸曲马多缓释片剂及其制备方法 |
| CZ300468B6 (cs) * | 2007-09-20 | 2009-05-27 | Zentiva, A. S | Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy |
| WO2009087690A2 (fr) * | 2008-01-11 | 2009-07-16 | Jubilant Organosys Limited | Composition pharmaceutique multiparticulaire à libération prolongée de carbamazépine et son procédé de fabrication |
| US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
| ES2536736T3 (es) * | 2008-09-04 | 2015-05-28 | Farnam Companies, Inc. | Formulaciones masticables de liberación sostenida |
| FR2938431B1 (fr) * | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
| EP2358360B1 (fr) | 2008-11-18 | 2016-09-14 | UCB Biopharma SPRL | Formules à libération prolongée comprenant un dérivé de 2-oxo-1-pyrrolidine |
| US20100233259A1 (en) * | 2008-12-12 | 2010-09-16 | Pascal Grenier | Dosage form of ropinirole |
| FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
| FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
| AR082189A1 (es) | 2010-07-06 | 2012-11-21 | Gruenenthal Gmbh | Formas de dosificacion gastrorretentivas, procedimiento |
| PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
| EP2976082A4 (fr) | 2013-03-15 | 2016-05-11 | Inspirion Delivery Technologies Llc | Compositions anti-abus et méthodes d'utilisation |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| JPS62103012A (ja) * | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | 多重顆粒 |
| US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| US5344657A (en) * | 1988-04-27 | 1994-09-06 | Elf Sanofi | Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them |
| US5260072A (en) * | 1990-08-30 | 1993-11-09 | Mcneil-Ppc, Inc. | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
| AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
| DE4428444A1 (de) * | 1994-08-11 | 1996-02-15 | Dresden Arzneimittel | Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
-
1996
- 1996-07-25 DE DE19630035A patent/DE19630035A1/de not_active Withdrawn
-
1997
- 1997-06-19 TW TW086108720A patent/TW495363B/zh not_active IP Right Cessation
- 1997-06-19 ZA ZA9705408A patent/ZA975408B/xx unknown
- 1997-07-18 US US08/896,629 patent/US5955104A/en not_active Expired - Lifetime
- 1997-07-19 AT AT97935532T patent/ATE213408T1/de active
- 1997-07-19 EP EP97935532A patent/EP0917463B1/fr not_active Expired - Lifetime
- 1997-07-19 CN CN97196651A patent/CN1111402C/zh not_active Expired - Lifetime
- 1997-07-19 JP JP50846698A patent/JP3631762B2/ja not_active Expired - Lifetime
- 1997-07-19 ES ES97935532T patent/ES2171268T3/es not_active Expired - Lifetime
- 1997-07-19 HU HU9903053A patent/HU227971B1/hu unknown
- 1997-07-19 BR BR9710761A patent/BR9710761A/pt not_active Application Discontinuation
- 1997-07-19 AU AU38491/97A patent/AU737121B2/en not_active Expired
- 1997-07-19 WO PCT/EP1997/003934 patent/WO1998004249A2/fr active IP Right Grant
- 1997-07-19 UA UA99021086A patent/UA52679C2/uk unknown
- 1997-07-19 PT PT97935532T patent/PT917463E/pt unknown
- 1997-07-19 SK SK98-99A patent/SK285300B6/sk not_active IP Right Cessation
- 1997-07-19 EE EEP199900031A patent/EE03742B1/xx unknown
- 1997-07-19 DK DK97935532T patent/DK0917463T3/da active
- 1997-07-19 RU RU99104404/14A patent/RU2201223C2/ru active
- 1997-07-19 IL IL12791597A patent/IL127915A/en not_active IP Right Cessation
- 1997-07-19 KR KR10-1999-7000586A patent/KR100474793B1/ko not_active IP Right Cessation
- 1997-07-19 DE DE59706441T patent/DE59706441D1/de not_active Expired - Lifetime
- 1997-07-19 CZ CZ0018599A patent/CZ296964B6/cs not_active IP Right Cessation
- 1997-07-19 PL PL97331387A patent/PL188834B1/pl unknown
- 1997-07-19 NZ NZ333822A patent/NZ333822A/xx not_active IP Right Cessation
- 1997-07-24 CA CA002211284A patent/CA2211284C/fr not_active Expired - Lifetime
- 1997-07-25 AR ARP970103383A patent/AR008002A1/es active IP Right Grant
-
1999
- 1999-01-21 NO NO19990261A patent/NO324207B1/no not_active IP Right Cessation
- 1999-02-09 BG BG103158A patent/BG63708B1/bg unknown
- 1999-07-08 US US09/349,564 patent/US6436438B1/en not_active Expired - Lifetime
- 1999-12-22 HK HK99106029A patent/HK1020876A1/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034377B2 (en) | 2004-09-01 | 2015-05-19 | Purdue Pharma, L.P. | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax |
| US9326959B2 (en) | 2004-09-01 | 2016-05-03 | Purdue Pharma, L.P. | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA52679C2 (uk) | Фармацевтична композиція, що містить велику кількість одиниць трамадолу, і спосіб її приготування | |
| FI78835C (fi) | Foerfarande foer framstaellning av en ny dipyridamol-retardform. | |
| US4927640A (en) | Controlled release beads having glass or silicon dioxide core | |
| RU2072840C1 (ru) | Твердая лекарственная форма пролонгированного действия для лечения сердечно-сосудистых заболеваний | |
| RU2239417C2 (ru) | Опиоидные анальгетики с контролируемым высвобождением активных веществ | |
| US5246714A (en) | Drug preparation | |
| JPH08506802A (ja) | 波状粒薬配給システム | |
| CA2031066A1 (fr) | Compositions pharmaceutiques | |
| JPH0530804B2 (fr) | ||
| JP4889897B2 (ja) | トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 | |
| SK280362B6 (sk) | Orálny farmaceutický prostriedok obsahujúci terape | |
| IL148407A (en) | Pharmacological forms for providing pony-suspended activity | |
| JP2003502359A (ja) | 新規製剤 | |
| US11883374B2 (en) | Lacosamide pharmaceutical composition and dosage form thereof | |
| DK164843B (da) | Theophyllin-retardpraeparat og fremgangsmaade til fremstilling heraf | |
| EP0063132A1 (fr) | Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme. | |
| EP1088554B1 (fr) | Association à libération prolongée contenant du mononitrate d'isosorbide et de l'acide acétylsalicylique | |
| US20240041803A1 (en) | Lacosamide pharmaceutical composition and dosage form thereof | |
| JPH06345649A (ja) | イプサピロン薬剤組成物 | |
| KR20230152051A (ko) | 멜라토닌을 포함하는 다층 펠릿의 제형(formulation of a multilayered pellet comprising melatonin) | |
| Remya et al. | International Journal of Modern Pharmaceutical Research | |
| MXPA99000903A (en) | Tramadol multiple unit formulations | |
| HRP920593A2 (en) | New drug preparation |